Comparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma.

ABSTRACT:

Purpose

Patients with glioblastoma (GBM) have a poor prognosis and are in desperate need of better therapies. As therapeutic decisions are increasingly guided by biomarkers, and EGFR abnormalities are common in GBM, thus representing a potential therapeutic target, we systematically evaluated methods of assessing EGFR amplification by multiple assays. Specifically, we evaluated correlation among fluorescence in situ hybridization (FISH), a standard assay for detecting EGFR amplification, with other methods.Experimental Design: Formalin-fixed, paraffin-embedded tumor samples were used for all assays. EGFR amplification was detected using FISH (N = 206) and whole-exome sequencing (WES, N = 74). EGFR mRNA expression was measured

SUBMITTER: Lassman AB 

PROVIDER: S-EPMC8291723 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature